Kurs & Likviditet
Beskrivning
Land | Norge |
---|---|
Lista | OB Match |
Sektor | Hälsovård |
Industri | Bioteknik |
2022-09-08 07:00:00
Oslo, Norway, September 8, 2022 - Oslo Børs has announced that Nykode
Therapeutics ASA (OSE: NYKD) will be included in the Oslo Børs Benchmark Index
(OSEBX) and Oslo Børs Mutual Fund Index (OSEFX), effective September 19, 2022.
Link to the release from Oslo Børs: https://newsweb.oslobors.no/message/570707
About Nykode Therapeutics
Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to
the discovery and development of novel immunotherapies for the treatment of
cancer and infectious diseases. Nykode's modular vaccine technology specifically
targets antigens to Antigen Presenting Cells, which are essential for inducing
rapid, strong and long-lasting antigen specific immune responses and eliciting
efficacious clinical responses.
Nykode's lead product candidates are VB10.16, a therapeutic vaccine for the
treatment of human papilloma virus (HPV)-16 induced malignancies which
demonstrated positive interim efficacy and safety results from its Phase II
trial for the treatment of cervical cancer